<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Beth N McLellan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maja Mockenhaupt, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2568216569">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein tyrosine kinase inhibitors (TKIs), which include selective and multikinase inhibitors, are a class of targeted anticancer medications approved for treatment of a number of solid tumors. The ability of TKIs to block molecular pathways specific to the proliferation of malignant cells has decreased the incidence of many of the adverse events caused by cytotoxic chemotherapy. However, TKIs bring their own set of specific dermatologic adverse events, which include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hand-foot skin reaction (HFSR)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seborrheic dermatitis-like eruption
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subungual splinter hemorrhages
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keratoacanthoma and squamous cell carcinomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hair changes such as alopecia and changes in hair color and/or texture
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keratosis pilaris-like eruption
        </p>
        <p>
        </p>
        <p>
         HFSR is the most common cutaneous adverse event caused by TKIs. Although rarely life-threatening, it can impair patients' quality of life and may lead to dose reductions or premature discontinuation of cancer treatment. HFSR secondary to TKIs will be reviewed in this topic. Other cutaneous adverse reactions to molecularly targeted therapy or conventional chemotherapy agents are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">
          "Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2496905160">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1607303287">
         <span class="h2">
          Incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of developing HFSR varies depending on the specific drug used and type of malignancy [
         <a href="#rid2">
          2-4
         </a>
         ]. The incidence rates of all-grade and high-grade HFSR range from 4.5 and 1.8 percent, respectively, in patients treated with
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         (a multitargeted tyrosine kinase inhibitor [TKI] used in the treatment of advanced renal cell carcinoma) to 60.5 and 20.4 percent, respectively, in patients taking
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         (a potent multitargeted TKI used in the treatment of advanced colorectal cancer)  (
         <a class="graphic graphic_table graphicRef109105" href="/z/d/graphic/109105.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. A meta-analysis of 57 studies (24,956 patients) found an overall incidence of all-grade and high-grade HFSR associated with vascular endothelial growth factor receptor (VEGFR)-TKIs of 35 percent (95% CI 28.6-41.6) and 9.7 percent (95% CI 7.3-12.3), respectively [
         <a href="#rid6">
          6
         </a>
         ]. The highest risk of all-grade HFSR was observed in patients with thyroid cancer and in patients receiving
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         . The highest risk of high-grade HFSR was observed in patients with thyroid cancer and in patients receiving regorafenib.
        </p>
        <p class="headingAnchor" id="H3612453792">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk factors for the development of HFSR are largely unknown, and the reaction is generally considered unpredictable. In a study of patients with renal cell carcinoma treated with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , female sex, good performance status, presence of lung and liver metastases at baseline, involvement of two or more organs, baseline white blood cell count above 5.5 x 10
         <sup>
          9
         </sup>
         cells/L, and week of therapy (with maximum risk at week 5) were predictive of grade 2 or greater HFSR [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The development of hypertension has been shown to be a risk factor for HFSR in patients treated with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and/or
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         [
         <a href="#rid7">
          7
         </a>
         ]. Polymorphisms of the VEGFR2 gene may also be associated with increased risk of developing HFSR [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Several genetic polymorphisms have been identified that increase risk of development of HFSR. Variants in the C-C motif chemokine ligand 5/C-C motif chemokine receptor 5 (CCL5/CCR5) pathway have been found to predict severe HFSR in patients with metastatic colorectal cancer treated with
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2547481248">
         <span class="h2">
          Association of hand-foot skin reaction with survival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have noted an association between the development of HFSR and other skin toxicities from TKIs and increased tumor response rate and overall survival rate [
         <a href="#rid7">
          7,9-11
         </a>
         ]. A Japanese prospective study examining patients with metastatic renal cell carcinoma treated with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         found that the median progression-free survival was 4.6 months in patients with HFSR versus 1.5 months in patients without [
         <a href="#rid11">
          11
         </a>
         ]. In a multivariate analysis, HFSR was the only predictive factor of progression-free survival, after adjusting for major patient clinical characteristics (eg, Eastern Cooperative Oncology Group performance status, Memorial Sloan-Kettering Cancer Center risk classification, lactate dehydrogenase). A study in Korea found that HFSR was a predictor of long-term survival (&gt;2 years) in patients treated with sorafenib for unresectable hepatocellular carcinoma [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Similarly, a national registry-based study from the Czech Republic including 705 patients with metastatic renal cell carcinoma treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         showed improved overall survival and progression-free survival in patients who developed HFSR compared with those who did not [
         <a href="#rid10">
          10
         </a>
         ]. These findings have been confirmed in multiple studies of patients with metastatic renal cell carcinoma treated with sunitinib [
         <a href="#rid13">
          13,14
         </a>
         ]. A study from Taiwan showed that in patients with soft tissue sarcoma treated with
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         , HFSR was an independent predictive factor for better treatment outcome [
         <a href="#rid15">
          15
         </a>
         ], and the appearance of HFSR was found to independently predict prolonged, progression-free survival in patients on
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         for hepatocellular carcinoma [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H846682622">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the exact mechanism leading to HFSR is unknown, it is thought that the inhibition of both the vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors is necessary to cause HFSR. Inhibition of either one of these receptors alone rarely leads to HFSR [
         <a href="#rid17">
          17
         </a>
         ]. Moreover, the observation that the incidence of HFSR increases when multikinase inhibitors are combined with VEGF receptor blockers such as
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and cediranib supports the theory that capillary microtrauma and/or inability to effectively repair vascular trauma at sites prone to mechanical and frictional stress results in drug extravasation and tissue damage [
         <a href="#rid18">
          18
         </a>
         ]. Further supporting the importance of vascular competence in the pathogenesis of HFSR is its increased incidence in patients treated with
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         , which uniquely inhibits the endothelium-specific TIE-2 receptor (important for vascular remodeling) [
         <a href="#rid17">
          17
         </a>
         ]. It was demonstrated via microarray analysis in a three-dimensional (3-D) epidermal model that
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         decreases expression of keratin 6A and serine protease inhibitor (SERPIN)B1 through inhibition of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated p38 mitogen-activated protein kinase (MAPK) signaling pathways [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3665646673">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main histopathologic features described for HFSR are similar to hand-foot syndrome (HFS) caused by cytotoxic chemotherapy. They include dyskeratotic keratinocytes at various stages of necrosis, vacuolar degeneration of the basal layer, and mild perivascular or lichenoid infiltrate that is predominantly lymphocytic [
         <a href="#rid20">
          20
         </a>
         ]. Necrotic subepidermal, intraepidermal, or subcorneal blisters can form followed by acanthosis with hyperkeratosis or parakeratosis. Cases of mild cystic degeneration of the eccrine coil and squamous metaplasia of the sweat glands have also been described [
         <a href="#rid21">
          21
         </a>
         ]. While the histologic features of HFS and HFSR can be similar, HFSR is more likely to show an increased rate of epidermal replication resulting in papillomatosis and acanthosis [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1188950118">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFSR appears in the first two to four weeks of treatment with tyrosine kinase inhibitors (TKIs) [
         <a href="#rid1">
          1
         </a>
         ]. It typically involves the palms and soles but can also occur in other friction-prone areas such as the interdigital web spaces and lateral aspects of the feet [
         <a href="#rid18">
          18
         </a>
         ]. It has been reported in unusual areas of excessive friction such as the fingertips used to operate a mobile device and the stump of an amputee [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         The typical appearance is that of focal, hyperkeratotic, callus-like lesions on an erythematous base in areas of pressure or friction such as the fingertips, heels and metatarsal areas, and over joints  (
         <a class="graphic graphic_picture graphicRef109140 graphicRef81824 graphicRef109135" href="/z/d/graphic/109140.html" rel="external">
          picture 1A-C
         </a>
         ). These lesions can begin as bullae or blisters [
         <a href="#rid17">
          17
         </a>
         ]. This clinical presentation differs from that of hand-foot syndrome (HFS) caused by cytotoxic chemotherapy, which typically presents with a diffuse erythema and scale involving the entire palm and sole  (
         <a class="graphic graphic_picture graphicRef77501 graphicRef79857" href="/z/d/graphic/77501.html" rel="external">
          picture 2A-B
         </a>
         ) [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/142102.html" rel="external">
          "Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'
         </a>
         .)
        </p>
        <p>
         HFSR lesions are usually painful; other symptoms may include paresthesia, tingling, burning, soreness of the palms and soles, and decreased tolerance of contact with hot objects [
         <a href="#rid1">
          1
         </a>
         ]. In severe cases, HFSR can limit the patient's ability to care for or dress themselves. Long-term cutaneous sequelae have not been reported.
        </p>
        <p class="headingAnchor" id="H2071694321">
         <span class="h1">
          IMPACT ON QUALITY OF LIFE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although HFSR is not life-threatening and is usually self-limiting, the symptom burden may significantly reduce the patient's health-related quality of life (HRQL) and lead to dose reductions or premature drug discontinuation. One study examining the data from 23 patients receiving
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         or
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         who completed the Skindex-16 (a self-reported, dermatology-specific quality of life [QoL] questionnaire) found a positive correlation between scores for symptoms and emotions and severity grade of HFSR, with the highest score reported for the symptoms domain [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Two instruments have been developed to assess specifically the HRQL in patients with hand-foot syndrome (HFS) and HFSR, the HFS-14 [
         <a href="#rid25">
          25
         </a>
         ], which assesses functional implications, and the newer HFSR and quality of life (HF-QoL) questionnaire [
         <a href="#rid26">
          26
         </a>
         ]. The latter evaluates the wider symptom burden, including physical well-being, activities of daily living, role function, social activities, emotional well-being, and mood. Although generally used in the setting of clinical trials, these instruments may be helpful in clinical practice to assess the patient's tolerance of treatment and overall clinical status.
        </p>
        <p class="headingAnchor" id="H583188773">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HFSR is usually straightforward, based upon the clinical appearance of hyperkeratotic plaques with painful erythema localized to areas of friction or pressure of the palms and soles  (
         <a class="graphic graphic_picture graphicRef109135" href="/z/d/graphic/109135.html" rel="external">
          picture 1C
         </a>
         ) and history of tyrosine kinase inhibitor (TKI) use. A skin biopsy is not usually performed, due to the potential morbidity associated with this procedure on the hands or feet.
        </p>
        <p class="headingAnchor" id="H549041105">
         <span class="h2">
          Grading of severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Grading the severity of HFSR is important to guide the approach to treatment and to facilitate the communication between dermatologist and oncologist. In clinical trials and oncology practices, the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, is the most commonly employed scale to assess the severity of cutaneous adverse reactions to cancer treatment  (
         <a class="graphic graphic_table graphicRef73474" href="/z/d/graphic/73474.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26,27
         </a>
         ]. Although HFSR is not included in CTCAE as its own category, "palmoplantar erythrodysesthesia" can be used to grade HFSR. It is also important to keep in mind the limitations of the CTCAE scale, which does not incorporate the patient's perception of severity or the potentially prolonged duration of HFSR [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1322784026">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HFSR includes other eruptions occurring primarily on the hands and feet:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hand-foot syndrome (HFS)
         </strong>
         – In patients receiving both a targeted agent and a cytotoxic chemotherapeutic agent, this distinction may be important to guide the reduction of the appropriate medication, if indicated. While both can be associated with pain and paresthesias, HFS due to cytotoxic chemotherapy typically presents with diffuse erythema and desquamation  (
         <a class="graphic graphic_picture graphicRef79857 graphicRef77501" href="/z/d/graphic/79857.html" rel="external">
          picture 2A-B
         </a>
         ), in contrast with the more focal hyperkeratotic lesions found in HFSR [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/142102.html" rel="external">
          "Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contact dermatitis
         </strong>
         – Allergic or irritant dermatitis involving the hands and/or feet presents with erythema and scale that are often more diffuse than HFSR  (
         <a class="graphic graphic_picture graphicRef82993" href="/z/d/graphic/82993.html" rel="external">
          picture 3
         </a>
         ) and are typically associated with pruritus rather than pain. (See
         <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">
          "Irritant contact dermatitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">
          "Clinical features and diagnosis of allergic contact dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tinea pedis and manuum
         </strong>
         – Skin infection from dermatophytes of the genus
         <em>
          Trichophyton
         </em>
         is characterized by erythema and scaling. The involvement of the hand is typically unilateral, resulting in the so-called "two-feet, one hand syndrome"  (
         <a class="graphic graphic_picture graphicRef57816" href="/z/d/graphic/57816.html" rel="external">
          picture 4
         </a>
         ). Dermatophyte infections are usually more pruritic than painful. A skin scraping from an affected area with a potassium hydroxide preparation will reveal fungal hyphae. (See
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea pedis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea manuum'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psoriasis
         </strong>
         – Psoriasis may present with erythema and scale of the palms and/or soles  (
         <a class="graphic graphic_picture graphicRef99481" href="/z/d/graphic/99481.html" rel="external">
          picture 5
         </a>
         ). However, it is often associated with characteristic nail changes, such as pitting  (
         <a class="graphic graphic_picture graphicRef70962" href="/z/d/graphic/70962.html" rel="external">
          picture 6
         </a>
         ) and oil spots  (
         <a class="graphic graphic_picture graphicRef66374" href="/z/d/graphic/66374.html" rel="external">
          picture 7
         </a>
         ), as well as symmetric plaques on other areas of the body  (
         <a class="graphic graphic_picture graphicRef54581" href="/z/d/graphic/54581.html" rel="external">
          picture 8
         </a>
         ). Patients often have a history of psoriasis; however, if a new presentation is suspected, a skin biopsy may be needed to differentiate psoriasis from HFSR. (See
         <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">
          "Psoriasis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyshidrotic dermatitis (eczema)
         </strong>
         – This type of eczema presents with deep-seated vesicles and blisters typically located on the volar aspect of the hands and feet  (
         <a class="graphic graphic_picture graphicRef55722 graphicRef83006 graphicRef82782" href="/z/d/graphic/55722.html" rel="external">
          picture 9A-C
         </a>
         ). In contrast with HFSR, dyshidrotic eczema is intensely pruritic and is not limited to areas of friction and pressure. (See
         <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">
          "Acute palmoplantar eczema (dyshidrotic eczema)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1252847531">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to management of HFSR should be individualized, depending upon severity, impact on the patient's activities of daily living, and need to continue anticancer treatment with multitargeted tyrosine kinase inhibitors (TKIs). A multidisciplinary approach to care, including oncologist, dermatologist, podiatrist, and nursing care, can be helpful.
        </p>
        <p>
         There are limited clinical trials specifically addressing the treatment of HFSR [
         <a href="#rid29">
          29
         </a>
         ]. Treatment is generally based upon clinical experience, expert consensus, and local guidelines [
         <a href="#rid17">
          17,21,29,30
         </a>
         ]. Our approach to management of HFSR is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H779678639">
         <span class="h2">
          General principles
         </span>
        </p>
        <p class="headingAnchor" id="H2913259583">
         <span class="h3">
          Treatment of hyperkeratosis and skin inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical keratolytic agents, such as creams or ointments containing topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         10 to 20%, can be applied focally to hyperkeratotic areas [
         <a href="#rid17">
          17
         </a>
         ]. Caution should be used as these agents can cause irritation and discomfort if applied to nonintact skin. Keratolytic medications can be used for all grades of HFSR  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). It is imperative that health care providers seek out any causes of friction in areas of HFSR; inspection of clothing and questioning regarding daily activities may be needed to identify potential exacerbating factors. (See
         <a class="local">
          'Prevention'
         </a>
         below.)
        </p>
        <p>
         Topical corticosteroids may be helpful to reduce skin inflammation in patients with grade 2 or higher HFSR. Since palms and soles are areas at low risk of skin atrophy from topical corticosteroids, superpotent corticosteroids (group 1  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )) can be safely used until cutaneous inflammation subsides. We typically use
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05%,
         <a class="drug drug_general" data-topicid="8514" href="/z/d/drug information/8514.html" rel="external">
          halobetasol
         </a>
         0.05%, or
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         dipropionate 0.05% in ointment, cream, or foam formulation, twice daily.
        </p>
        <p class="headingAnchor" id="H2374572074">
         <span class="h3">
          Treatment of pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical analgesics such as topical
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         4 to 6% in gels, creams, or patches can be used for symptomatic pain relief for grades 1 and 2 HFSR. Systemic pain medications such as nonsteroidal anti-inflammatory drugs, opioids, or gamma-aminobutyric acid (GABA) agonists (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) may be of use in grade 2 or higher HFSR, if no contraindications exist [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H314760125">
         <span class="h3">
          Prevention of infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although secondary infection in HFSR has not been described, given the patient's immunocompromised status, the disruption of the skin barrier by trauma or inflammation is a concern as a possible portal of entry for infection. Open or oozing areas of the skin may be treated with antiseptics (eg, potassium permanganate,
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         gluconate, diluted bleach) or topical antibiotics (eg,
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         2%,
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         1%) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H647944625">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small studies and case reports suggest a beneficial effect of heparin-containing ointment [
         <a href="#rid31">
          31
         </a>
         ], hydrocolloid dressing containing ceramide [
         <a href="#rid32">
          32
         </a>
         ], vitamin E [
         <a href="#rid33">
          33
         </a>
         ], narrowband ultraviolet B phototherapy [
         <a href="#rid34">
          34
         </a>
         ], and topical
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         [
         <a href="#rid35">
          35
         </a>
         ] in the treatment of HFSR. However, these treatments are rarely used due to the scant evidence of efficacy, costs, and limited accessibility of some of them.
        </p>
        <p class="headingAnchor" id="H2393998617">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no evidence from randomized trials to determine the best reactive strategy for HFSR. Our approach, based upon clinical experience and expert consensus, is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid17">
          17,21,29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1644229316">
         <span class="h3">
          Patients with grade 1 hand-foot skin reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For mild, grade 1 HFSR  (
         <a class="graphic graphic_table graphicRef73474" href="/z/d/graphic/73474.html" rel="external">
          table 2
         </a>
         ), dose modifications are not needed  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). Patients should avoid using hot water and should regularly apply keratolytic emollients containing topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         10% three times per day. (See
         <a class="local">
          'Treatment of hyperkeratosis and skin inflammation'
         </a>
         above.)
        </p>
        <p>
         We generally reassess patients after two weeks of treatment. If the reaction has not improved or has worsened, patients are treated in the same way as those with grade 2 rash.
        </p>
        <p class="headingAnchor" id="H4212125369">
         <span class="h3">
          Patients with grade 2 hand-foot skin reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For grade 2 HFSR, topical treatment includes a superpotent topical corticosteroid (group 1  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )) to be applied to the erythematous areas  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). We use
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% ointment, foam, or solution twice daily and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         4 to 6% cream or patches during the day.
        </p>
        <p>
         Oral analgesics, including nonsteroidal anti-inflammatory drugs, opioids, or GABA agonists (eg,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) may be given as needed to reduce skin pain and discomfort. (See
         <a class="local">
          'Treatment of hyperkeratosis and skin inflammation'
         </a>
         above.)
        </p>
        <p>
         We generally reassess patients after two weeks of treatment. If the reaction has not improved or has worsened, patients are treated in the same way as those with grade 3 rash [
         <a href="#rid17">
          17,21
         </a>
         ].
        </p>
        <p>
         For grade 2 reaction that does not respond to treatment, the TKI dose can be decreased as per the prescribing information. If the HFSR does not improve, the TKI can be temporarily discontinued as for patients with grade 3 HFSR, until symptoms improve to grade 0 or 1, and then resumed at a lower dose as per prescribing information [
         <a href="#rid17">
          17,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H918914925">
         <span class="h3">
          Patients with grade 3 hand-foot skin reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with grade 3 or intolerable grade 2 reaction that does not respond to treatment, a temporary interruption of the TKI is indicated  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). The TKI should be held for at least seven days or until toxicity resolves and then resumed at a lower dose as per the prescribing information. If the adverse reaction does not recur, dose escalation can be attempted.
        </p>
        <p>
         Topical treatments and oral pain medications are continued as for grade 2.
        </p>
        <p class="headingAnchor" id="H183169781">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to initiating treatment with multitargeted tyrosine kinase inhibitors (TKIs), we instruct patients to adopt prophylactic measures that may reduce the likelihood or severity of HFSR  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). These include [
         <a href="#rid17">
          17,21,29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          Urea
         </a>
         10% cream three times per day to palms and soles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examining hands and feet for presence of calluses. Hyperkeratotic areas and calluses should be removed through a manicure and/or pedicure, using appropriately sterilized instruments. Keratotic skin can be gently exfoliated using a pumice stone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keeping skin of hands and feet well-moisturized using bland emollients or topical urea-based creams, especially after washing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seeking evaluation by an orthotist for an orthotic device is encouraged for patients with evidence of abnormal weight bearing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding exposing hands and feet to hot water, as this is believed to exacerbate symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding constrictive footwear and excessive friction on the skin when applying lotions, getting massages, or performing everyday tasks such as typing or using handheld electronic devices.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding vigorous exercise that places undue stress on the palms and/or soles of the feet, particularly during the first month of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wearing shoes with padded insoles throughout treatment to reduce pressure on the feet. Thick cotton gloves or socks can be worn to prevent injury and keep the palms and soles dry.
        </p>
        <p>
        </p>
        <p>
         The use of a 10% topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         cream for the prevention of HFSR has been evaluated in a randomized trial of 871 patients receiving
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         for advanced hepatocellular carcinoma [
         <a href="#rid36">
          36
         </a>
         ]. In this study, patients were treated with 10% topical urea cream three times per day plus best supportive care or best supportive care alone excluding all creams. The incidence of any grade HFSR within 12 weeks of starting sorafenib was modestly but significantly lower with the topical urea cream (56 versus 74 percent, odds ratio [OR] 0.46, 95% CI 0.34-0.61) as was the incidence of grade (≥2) HFSR (21 versus 29 percent, OR 0.64, 95% CI 0.47-0.87). However, due to the lack of a placebo (vehicle) group, it is unclear whether the beneficial effect of treatment is associated with topical urea or the cream itself.
        </p>
        <p>
         Another 12-week trial comparing
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         20% cream and placebo in 288 patients with hepatocellular carcinoma treated with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         found a trend towards lower cumulative incidence of any-grade and severe HFSR in the urea group [
         <a href="#rid37">
          37
         </a>
         ]. At 12 weeks, the patients using urea cream had a lower incidence of grade ≥2 HFSR and a significantly better quality of life (HF-QoL) score.
        </p>
        <p class="headingAnchor" id="H1301579201">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Hand-foot skin reaction (HFSR) is the most common cutaneous adverse reaction to treatment with multitargeted tyrosine kinase inhibitors (TKIs). The incidence rates of all-grade and high-grade HFSR vary, depending on the specific drug used and type of malignancy  (
         <a class="graphic graphic_table graphicRef109105" href="/z/d/graphic/109105.html" rel="external">
          table 1
         </a>
         ), and appear to be more common in females. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – HFSR appears in the first two to four weeks of treatment with TKIs. It typically presents with focal, hyperkeratotic, callus-like lesions and erythema on the palms and soles  (
         <a class="graphic graphic_picture graphicRef109140 graphicRef81824 graphicRef109135" href="/z/d/graphic/109140.html" rel="external">
          picture 1A-C
         </a>
         ) but can also occur in other friction-prone areas such as the interdigital web spaces and lateral aspects of the feet. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of HFSR is usually straightforward, based upon the clinical appearance and history of TKI use. The severity is graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0  (
         <a class="graphic graphic_table graphicRef73474" href="/z/d/graphic/73474.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Prior to initiating treatment with multitargeted TKIs, instruct patients to adopt prophylactic measures that may reduce the likelihood or severity of HFSR, including hand and foot care to eliminate hyperkeratoses, podiatric consultation, minimization of friction and pressure, and use of emollients or topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         10 to 20% three times per day. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Reactive treatment is based upon clinical experience, consensus statements, and local guidelines. Our approach is illustrated in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with grade 1 HFSR  (
         <a class="graphic graphic_table graphicRef73474" href="/z/d/graphic/73474.html" rel="external">
          table 2
         </a>
         ), we suggest keratolytic moisturizers (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We use topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         10 to 20% creams or ointments and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         4 to 6% cream or patches. (See
         <a class="local">
          'Patients with grade 1 hand-foot skin reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with grade 2 HFSR, we suggest super high-potency topical corticosteroids (group 1  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         )) and oral analgesics in addition to topical therapies as for grade 1 (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We use
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% ointment, foam, or solution twice daily. If the reaction does not improve, the TKI dose can be lowered as per the prescribing information until symptoms improve to grade 0 or 1 and then resumed at a lower dose as per prescribing information. (See
         <a class="local">
          'Patients with grade 2 hand-foot skin reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with grade 3 HFSR or intolerable grade 2 HFSR that does not respond to treatment, we suggest to hold the TKI dose for at least seven days or until HFSR resolves (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In addition, we continue topical medications and oral analgesics as for grade 1 and 2. Once the toxicity has resolved, treatment with the TKI can be resumed at a lower dose. If the adverse reaction does not recur, dose escalation can be attempted. (See
         <a class="local">
          'Patients with grade 3 hand-foot skin reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1737810694">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Mario E Lacouture, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011; 24:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 2012; 7:e42875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dranitsaris G, Vincent MD, Yu J, et al. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012; 23:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya N, Narita S, Inoue T, et al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs 2013; 24:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013; 31:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding F, Liu B, Wang Y. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol 2020; 83:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suenaga M, Schirripa M, Cao S, et al. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 2018; 17:e395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012; 23:3137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano K, Komatsu K, Kubo T, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol 2013; 43:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho YY, Yu SJ, Lee HW, et al. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021; 8:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagyiványi K, Budai B, Bíró K, et al. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 2016; 14:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucharz J, Dumnicka P, Kuzniewski M, et al. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Tumori 2015; 101:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang PW, Chou WC, Shen WC, et al. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. Asia Pac J Clin Oncol 2018; 14:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapposelli IG, Tada T, Shimose S, et al. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int 2021; 41:2997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 2015; 26:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida A, Yamamoto K, Ishida T, et al. Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models. Exp Dermatol 2021; 30:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone SL, Jameson G, Von Hoff D, Lacouture ME. Blackberry-induced hand-foot skin reaction to sunitinib. Invest New Drugs 2009; 27:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai SE, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nardone B, Hensley JR, Kulik L, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 2012; 11:e61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson RT, Keating KN, Doll HA, Camacho F. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist 2015; 20:831.
          </a>
         </li>
         <li class="breakAll">
          Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011; 9:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JR, Yang CR, Cheng CL, et al. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Support Care Cancer 2013; 21:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinohara N, Nonomura N, Eto M, et al. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol 2014; 25:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozkurt Duman B, Kara B, Oguz Kara I, et al. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. J BUON 2011; 16:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung CT, Chiang CP, Wu BY. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. J Dermatol 2012; 39:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meadows KL, Rushing C, Honeycutt W, et al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015; 23:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YS, Jung YK, Kim JH, et al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer 2020; 140:19.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 103060 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21910797" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22912756" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22228446" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23237922" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23700287" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30991119" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20630084" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29606345" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22469363" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22700990" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23956442" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34169044" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26774206" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26045121" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29900662" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34250737" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26034039" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24795111" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33135264" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19923864" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18779536" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18998055" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Blackberry-induced hand-foot skin reaction to sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17235051" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hand-foot and stump syndrome to sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23135095" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21964002" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26084809" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26084809" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17991931" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Patient-reported outcomes and the evolution of adverse event reporting in oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19276294" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21465734" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23262811" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24351402" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22331734" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22724918" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25341548" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25667293" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33039810" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
